Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine

Area of Science:

• Neurology
• Pharmacology
• Geriatrics

Background:

• Clinical practice guidelines are essential for evidence-based dementia treatment.
• Alzheimer's disease (AD) and other dementias require specific pharmacologic interventions.
• Cholinesterase inhibitors and NMDA receptor antagonists are key drug classes for dementia management.

Purpose of the Study:

• To provide evidence-based recommendations for dementia pharmacologic treatment.
• To guide clinicians on using cholinesterase inhibitors and NMDA receptor antagonists.
• To support improved patient outcomes in dementia care.

Main Methods:

• Systematic literature reviews using the PICO framework.
• Evaluation of randomized controlled trials and observational studies by a multidisciplinary expert panel.
• Grading of recommendations using the GRADE methodology for evidence quality and strength.

Main Results:

• Strong recommendation for cholinesterase inhibitors in AD to improve cognition and daily function (moderate evidence).
• Conditional recommendation for cholinesterase inhibitors in vascular dementia and Parkinson's disease dementia; strong recommendation for Lewy body dementia.
• Strong recommendation for NMDA receptor antagonist (memantine) in moderate to severe AD for cognitive and functional improvements.
• Both drug classes demonstrated favorable safety profiles with manageable side effects.

Conclusions:

• Standardized, evidence-based pharmacologic recommendations for dementia management.
• Guidance on cholinesterase inhibitors and NMDA receptor antagonists to support clinical decision-making.
• Future updates will incorporate emerging treatments like amyloid-targeting therapies for advanced dementia care.